How much is the Neuromuscular Disease Therapeutics Market market?

The neuromuscular disease therapeutics market market size is estimated to grow at $$ 9.17 bn in 2023. Read More

What is the growth rate of the Neuromuscular Disease Therapeutics Market market?

The growth rate of the neuromuscular disease therapeutics market year-over-year is 11.44%. Read More

Which region held the largest market share in the Neuromuscular Disease Therapeutics Market market?

North America is the region to held the largest market share with 43% growth. Read More

Who are the key players in the Neuromuscular Disease Therapeutics Market market?

AbbVie Inc., Aquestive Therapeutics Inc., argenx SE, AstraZeneca PLC, Biogen Inc., CuraVac, F. Hoffmann La Roche Ltd., Grifols SA, Merck and Co. Inc., Nippon Shinyaku .... Read More

Which Segment has the largest market share in the Neuromuscular Disease Therapeutics Market market?

Type is the segment that has the largest market share in the market. Read More

Neuromuscular Disease Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Mar 2024
Pages: 165
SKU: IRTNTR71996

Enjoy complimentary customisation on priority with our Enterprise License!

Neuromuscular Disease Therapeutics Market Forecast 2024-2028

The global neuromuscular disease therapeutics market size is estimated to grow by USD 9.17 billion, at a CAGR of 11.44% between 2023 and 2028.

A substantial unmet need exists for neuromuscular disease therapeutics due to the scarcity of approved safe and effective drugs. With over 30 highly morbid and fatal neuromuscular diseases lacking adequate treatment options, the market is constrained by a limited number of approved drugs. Existing treatments often pose severe and multiple side effects. Research in the neuromuscular disease domain is in its early stages, with drugs primarily in early clinical trials or preclinical phases. Focused efforts are directed towards fatal diseases like Duchenne muscular dystrophy and amyotrophic lateral sclerosis, aiming to develop novel therapies, including disease-modifying drugs. Regenerative therapies such as gene and cell therapies offer promising avenues to reverse the damage and enhance patient life expectancy. This unmet need propels the growth of the market during the forecast period.

What will be the Size of the Market During the Forecast Period?

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global neuromuscular disease therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global neuromuscular disease therapeutics market 2018 - 2022 ($ billion)

4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

4.3 End-user Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – End-user Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Biologics - Market size and forecast 2023-2028
- Exhibit 34: Chart on Biologics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Biologics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Biologics - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Biologics - Year-over-year growth 2023-2028 (%)

6.4 Small molecules - Market size and forecast 2023-2028
- Exhibit 38: Chart on Small molecules - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Small molecules - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Small molecules - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Small molecules - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ billion)
- Exhibit 43: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by End-user

7.1 Market segments
- Exhibit 44: Chart on End-user - Market share 2023-2028 (%)
- Exhibit 45: Data Table on End-user - Market share 2023-2028 (%)

7.2 Comparison by End-user
- Exhibit 46: Chart on Comparison by End-user
- Exhibit 47: Data Table on Comparison by End-user

7.3 Hospitals - Market size and forecast 2023-2028
- Exhibit 48: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
- Exhibit 49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
- Exhibit 50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)

7.4 Clinics - Market size and forecast 2023-2028
- Exhibit 52: Chart on Clinics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on Clinics - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Clinics - Year-over-year growth 2023-2028 (%)

7.5 Others - Market size and forecast 2023-2028
- Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by End-user
- Exhibit 60: Market opportunity by End-user ($ billion)
- Exhibit 61: Data Table on Market opportunity by End-user ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Canada - Market size and forecast 2023-2028
- Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 China - Market size and forecast 2023-2028
- Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ billion)
- Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings

12.4 Aquestive Therapeutics Inc.
- Exhibit 115: Aquestive Therapeutics Inc. - Overview
- Exhibit 116: Aquestive Therapeutics Inc. - Business segments
- Exhibit 117: Aquestive Therapeutics Inc. - Key offerings
- Exhibit 118: Aquestive Therapeutics Inc. - Segment focus

12.5 argenx SE
- Exhibit 119: argenx SE - Overview
- Exhibit 120: argenx SE - Product / Service
- Exhibit 121: argenx SE - Key offerings

12.6 AstraZeneca PLC
- Exhibit 122: AstraZeneca PLC - Overview
- Exhibit 123: AstraZeneca PLC - Product / Service
- Exhibit 124: AstraZeneca PLC - Key news
- Exhibit 125: AstraZeneca PLC - Key offerings

12.7 Biogen Inc.
- Exhibit 126: Biogen Inc. - Overview
- Exhibit 127: Biogen Inc. - Product / Service
- Exhibit 128: Biogen Inc. - Key news
- Exhibit 129: Biogen Inc. - Key offerings

12.8 F. Hoffmann La Roche Ltd.
- Exhibit 130: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 131: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 132: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 133: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 134: F. Hoffmann La Roche Ltd. - Segment focus

12.9 Grifols SA
- Exhibit 135: Grifols SA - Overview
- Exhibit 136: Grifols SA - Business segments
- Exhibit 137: Grifols SA - Key offerings
- Exhibit 138: Grifols SA - Segment focus

12.10 Merck and Co. Inc.
- Exhibit 139: Merck and Co. Inc. - Overview
- Exhibit 140: Merck and Co. Inc. - Business segments
- Exhibit 141: Merck and Co. Inc. - Key news
- Exhibit 142: Merck and Co. Inc. - Key offerings
- Exhibit 143: Merck and Co. Inc. - Segment focus

12.11 Nippon Shinyaku Co. Ltd.
- Exhibit 144: Nippon Shinyaku Co. Ltd. - Overview
- Exhibit 145: Nippon Shinyaku Co. Ltd. - Business segments
- Exhibit 146: Nippon Shinyaku Co. Ltd. - Key offerings
- Exhibit 147: Nippon Shinyaku Co. Ltd. - Segment focus

12.12 Novartis AG
- Exhibit 148: Novartis AG - Overview
- Exhibit 149: Novartis AG - Business segments
- Exhibit 150: Novartis AG - Key news
- Exhibit 151: Novartis AG - Key offerings
- Exhibit 152: Novartis AG - Segment focus

12.13 Pfizer Inc.
- Exhibit 153: Pfizer Inc. - Overview
- Exhibit 154: Pfizer Inc. - Product / Service
- Exhibit 155: Pfizer Inc. - Key news
- Exhibit 156: Pfizer Inc. - Key offerings

12.14 Roivant Sciences Ltd.
- Exhibit 157: Roivant Sciences Ltd. - Overview
- Exhibit 158: Roivant Sciences Ltd. - Product / Service
- Exhibit 159: Roivant Sciences Ltd. - Key offerings

12.15 Santhera Pharmaceuticals Holding AG
- Exhibit 160: Santhera Pharmaceuticals Holding AG - Overview
- Exhibit 161: Santhera Pharmaceuticals Holding AG - Product / Service
- Exhibit 162: Santhera Pharmaceuticals Holding AG - Key offerings

12.16 Sarepta Therapeutics Inc.
- Exhibit 163: Sarepta Therapeutics Inc. - Overview
- Exhibit 164: Sarepta Therapeutics Inc. - Product / Service
- Exhibit 165: Sarepta Therapeutics Inc. - Key offerings

12.17 Takeda Pharmaceutical Co. Ltd.
- Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 169: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 170: Inclusions checklist
- Exhibit 171: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 172: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 173: Research methodology
- Exhibit 174: Validation techniques employed for market sizing
- Exhibit 175: Information sources